APOE Genotype (Cardiovascular Risk)

What is the APOE Genotype (Cardiovascular Risk) Test?

The APOE Genotype Test from BiomarkersLabs.com identifies the specific allele combination at the APOE gene — the gene encoding Apolipoprotein E — from a single whole blood sample. The APOE gene has three common allelic variants: ε2, ε3, and ε4. Every individual inherits two alleles — one from each parent — producing six possible genotype combinations: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4. These genotypes encode the three ApoE protein isoforms — ApoE2, ApoE3, and ApoE4 — which differ in receptor binding affinity and produce markedly different lipoprotein metabolism phenotypes, cardiovascular risk profiles, and neurological disease susceptibilities. The APOE genotype is permanent and does not change throughout life — a single test result provides definitive genetic information that informs cardiovascular risk stratification, treatment planning, dietary guidance, and, where clinically appropriate, neurological risk counselling for the duration of the patient’s life. Specimens are processed through CLIA-certified partner laboratories (Quest Diagnostics and LabCorp) for USA orders, with IVDR-compliant partner laboratories serving EU and UK practitioners. Results are delivered to your secure BiomarkersLabs.com practitioner portal within 5–7 business days of specimen receipt.

The cardiovascular implications of APOE genotype are substantial and clinically actionable. ApoE mediates the hepatic clearance of VLDL remnants, IDL, and chylomicron remnants through LDL receptor and LDL receptor-related protein binding. The three isoforms differ critically in this binding affinity — ApoE3 binds normally, ApoE2 binds with only approximately 2% of normal affinity, and ApoE4 binds with the highest affinity but through a pathway that paradoxically downregulates LDL receptor expression and impairs VLDL remnant clearance in a manner that elevates circulating LDL cholesterol. These mechanistic differences translate into measurably different LDL cholesterol levels, VLDL remnant accumulation, and cardiovascular event rates across the three genotype classes. ε4 carriers — who represent approximately 25% of the general population — have consistently higher LDL cholesterol than ε3/ε3 individuals under identical dietary conditions, respond less strongly to dietary saturated fat reduction, and have an independently elevated lifetime risk of coronary artery disease. ε2/ε2 homozygotes have the lowest LDL cholesterol of any genotype but accumulate VLDL remnants and IDL and are predisposed to type III hyperlipoproteinaemia — familial dysbetalipoproteinaemia — the most atherogenic remnant lipoprotein accumulation disorder. ε2/ε3 heterozygotes have naturally low LDL cholesterol and the lowest population cardiovascular risk.

Beyond cardiovascular risk, the APOE ε4 allele is the most significant known single-gene risk factor for late-onset Alzheimer’s disease. Carrying one ε4 allele increases Alzheimer’s disease risk approximately three-fold compared to ε3/ε3; carrying two ε4 alleles (ε4/ε4) increases risk approximately eight to twelve-fold. This neurological risk dimension means that APOE genotyping has clinical implications that extend well beyond lipid management — it is relevant to dementia risk counselling, preventive neurology, lifestyle guidance for brain health, and patient-centred planning for long-term cognitive health. Practitioners ordering this test should be prepared to provide pre- and post-test counselling around both the cardiovascular and neurological risk dimensions of the result, or to refer to appropriate specialist services for neurological risk discussion. CLIA-certified (USA) and IVDR-compliant (EU/UK). Licensed practitioners only through BiomarkersLabs.com.

What does this test measure?

APOE Genotype (ε2/ε3/ε4 alleles) — The definitive genetic identification of the two APOE alleles inherited by the patient — one from each parent — producing one of six possible genotype combinations: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, or ε4/ε4. The result is reported as the genotype combination and interpreted in the context of the associated cardiovascular and neurological risk profile for that genotype. The ε3/ε3 genotype — carried by approximately 60% of the general population — is the reference genotype associated with normal lipoprotein metabolism and intermediate risk. ε4/ε4 — carried by approximately 2–3% of the population — confers the highest cardiovascular LDL-related risk and the highest Alzheimer’s disease susceptibility. ε2/ε2 — carried by approximately 1% of the population — is associated with the lowest LDL cholesterol but the highest VLDL remnant accumulation risk and type III hyperlipoproteinaemia susceptibility. The APOE genotype is determined at conception and remains constant throughout life — it does not require repeat testing.

Clinical indications

Cardiovascular genetic risk stratification — APOE genotype provides definitive genetic characterisation of a patient’s inherited lipoprotein metabolism phenotype, identifying ε4 carriers at elevated LDL-driven cardiovascular risk and ε2/ε2 individuals at risk of VLDL remnant accumulation and type III hyperlipoproteinaemia; this information informs long-term cardiovascular risk stratification independently of current lipid values.

Statin response prediction and pharmacogenomics — APOE genotype influences the LDL cholesterol response to statin therapy; ε4 carriers generally achieve greater absolute LDL-C reduction with statins because they start with higher baseline LDL-C, but may require more intensive therapy to reach target; ε2 carriers have naturally low LDL-C and may have limited additional statin benefit for LDL reduction but may benefit from fibrate therapy for VLDL remnant management.

LDL metabolism genetic assessment — patients with persistently elevated LDL cholesterol despite adequate statin therapy, or patients with complex lipid patterns that do not respond as expected to standard interventions, benefit from APOE genotyping to determine whether the LDL elevation has a genetic mechanistic basis related to ApoE-mediated clearance that requires a different therapeutic approach.

Alzheimer’s disease risk co-assessment — patients with a personal or family history of cognitive decline, dementia, or Alzheimer’s disease who request genetic risk information benefit from APOE genotyping, which identifies ε4 carriers at substantially elevated Alzheimer’s disease susceptibility; this result should be disclosed with appropriate pre- and post-test counselling given its neurological significance.

Family history of premature cardiovascular disease genetic workup — first-degree relatives of patients with premature atherosclerotic events should have APOE genotyping as part of their comprehensive cardiovascular genetic workup, to determine whether an inherited ε4-driven LDL metabolism phenotype is contributing to familial cardiovascular risk.

Type III hyperlipoproteinaemia diagnosis and confirmation — patients with elevated VLDL remnants, elevated IDL, and a characteristic mixed hyperlipidaemia pattern that does not fit standard dyslipidaemia should have APOE genotyping to confirm or exclude ε2/ε2 homozygosity — the genetic prerequisite for type III hyperlipoproteinaemia, which requires fibrate-first rather than statin-first therapy.

Dietary response prediction and precision nutrition — ε4 carriers are significantly more sensitive to dietary saturated fat in terms of LDL cholesterol elevation, and benefit most from Mediterranean and plant-rich dietary patterns that minimise saturated fat; ε2 carriers are more responsive to dietary fat modification for VLDL remnant control; APOE genotyping enables genotype-specific dietary guidance that is more precisely targeted than population-average nutritional recommendations.

Preventive neurology and brain health programme integration — practitioners running preventive neurology or longevity programmes use APOE genotyping to identify ε4 carriers who may benefit from intensified brain health interventions including aerobic exercise, sleep optimisation, dietary modification, and emerging neuroprotective strategies; this test is increasingly ordered as part of comprehensive preventive health panels in functional and integrative medicine settings.

Complex dyslipidaemia mechanistic clarification — in patients with dyslipidaemia that does not respond to standard therapy or produces unexpected lipid patterns, APOE genotyping provides the mechanistic genetic framework to understand why — distinguishing ApoE4-driven LDL elevation from ApoE2-driven remnant accumulation from ApoE3 reference metabolism, and directing appropriate pharmacological intervention accordingly.

Pre-treatment genetic baseline before initiating lipid-lowering therapy — documenting APOE genotype before starting statin or other lipid-lowering therapy provides the genetic context for interpreting treatment response and setting appropriately genotype-adjusted treatment targets; ε4 carriers may need more aggressive LDL-C targets given their genotype-elevated baseline risk.

Sample type and collection

Sample Type: Blood (whole blood)

Fasting Required: No — fasting is not required for APOE genotyping. Genetic DNA analysis is not affected by the patient’s metabolic or dietary state at the time of collection. The patient may attend their collection appointment at any time of day without fasting preparation.

Collection Method: Venepuncture at an approved collection site with whole blood collection into EDTA tubes. USA patients attend a Quest Diagnostics or LabCorp patient service centre using the requisition generated through your BiomarkersLabs.com portal. EU, UK, and Canada patients are directed to partner collection networks in their region.

Specimen Timing Note: There are no specific timing restrictions for APOE genotype collection — the result is determined by the patient’s germline DNA, which is identical in every nucleated cell and is not affected by time of day, metabolic state, acute illness, medications, or any other physiological variable. Collection can proceed at any convenient time for the patient. If concurrent lipid markers are being ordered alongside the genotype test, standard fasting requirements apply to those markers only.

Counselling Note: Practitioners should be aware that APOE genotype results carry neurological risk implications — specifically regarding Alzheimer’s disease risk in ε4 carriers — in addition to their cardiovascular applications. Pre-test discussion of the scope of information that may be revealed, and post-result counselling capacity, is recommended best practice before ordering this test. Patients who wish to remain unaware of their Alzheimer’s disease genetic risk should be informed of this dimension before collection.

Turnaround time

5–7 business days from specimen receipt at the processing laboratory. Turnaround begins upon confirmed specimen receipt — not from the date of patient collection. Genetic testing requires additional analytical processing steps compared to biochemical assays, which accounts for the longer turnaround relative to standard lipid markers. The ordering practitioner receives an automated email notification when results are available in their BiomarkersLabs.com practitioner portal. Results are never sent to the patient and are not accessible outside the verified practitioner portal.

Availability

USA · EU · UK · Canada

Available to licensed practitioners ordering for patients in all US states. This test does not carry a New York state restriction — it can be ordered for patients in New York without limitation. For EU, UK, and Canadian practitioners, ordering and collection logistics are managed through your BiomarkersLabs.com portal on registration.

Compliance and certifications

CLIA Certified — All USA specimens processed by CLIA-certified Quest Diagnostics and LabCorp partner laboratories meeting federal standards for clinical laboratory quality.

IVDR Compliant — EU and UK specimens processed in compliance with the EU In Vitro Diagnostic Regulation (EU) 2017/746.

CE Marked — All diagnostic assays used for EU and UK specimens carry CE marking confirming conformity with applicable European IVD standards.

HIPAA Compliant — All USA patient data handled in full compliance with HIPAA. Results delivered to the ordering practitioner’s portal only — never to the patient.

GDPR Compliant — All EU and UK practitioner and patient data processed in accordance with the General Data Protection Regulation.

PIPEDA Compliant — Canadian data handled in compliance with the Personal Information Protection and Electronic Documents Act.

How to order

This test is available exclusively to licensed healthcare practitioners. Register free at BiomarkersLabs.com — licence verification takes 1–2 business days. USA practitioners with a valid NPI number are verified automatically. Once your account is active, search for the APOE Genotype Test in your portal, enter patient details, and submit the order. Your patient receives a requisition to attend their nearest approved collection site — no fasting preparation is required. Results are returned to your portal within 5–7 business days of specimen receipt. All pricing is visible after login — no subscription required, pay per test.

This test is available exclusively to licensed healthcare practitioners. Results are delivered to the ordering practitioner’s secure portal only — never directly to patients. Licence verification required (1–2 business days). BiomarkersLabs.com does not accept patient self-referrals.

Frequently Asked Questions — APOE Genotype Test

What does the APOE Genotype test identify?

The APOE Genotype test identifies the specific combination of two APOE alleles inherited by the patient — one from each biological parent — producing one of six possible genotype results: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, or ε4/ε4. Each genotype encodes a different combination of ApoE protein isoforms — ApoE2, ApoE3, and ApoE4 — which have markedly different receptor binding affinities and produce distinct lipoprotein metabolism phenotypes, cardiovascular risk profiles, and neurological disease susceptibilities. The result is permanent — it does not change throughout the patient’s life and does not require repeat testing.

What are the six APOE genotypes and what do they mean for cardiovascular risk?

ε3/ε3 is the most common genotype, carried by approximately 60% of the population, and represents the reference lipoprotein metabolism phenotype with normal LDL clearance and intermediate cardiovascular risk. ε3/ε4 is carried by approximately 25% of the population and is associated with elevated LDL cholesterol, greater sensitivity to dietary saturated fat, and increased cardiovascular and Alzheimer’s disease risk. ε4/ε4 is carried by approximately 2–3% of the population and confers the highest LDL cholesterol levels, the greatest cardiovascular risk, and the highest Alzheimer’s disease susceptibility of any genotype. ε2/ε3 is carried by approximately 11% of the population and is associated with the lowest LDL cholesterol and the lowest population cardiovascular risk, though ε2 carriers require monitoring for VLDL remnant accumulation. ε2/ε4 produces intermediate effects with the contrasting actions of the ε2 (low LDL, remnant accumulation tendency) and ε4 (high LDL) alleles partially offsetting each other. ε2/ε2 is carried by approximately 1% of the population and is associated with very low LDL cholesterol but markedly elevated VLDL remnants and IDL — predisposing to type III hyperlipoproteinaemia when additional metabolic triggers such as obesity, diabetes, or hypothyroidism are present.

Why does APOE genotype affect Alzheimer’s disease risk?

The APOE ε4 allele is the most significant known genetic risk factor for late-onset Alzheimer’s disease. ApoE plays a critical role in the brain’s lipid metabolism, amyloid-beta clearance, and neuronal repair pathways. ApoE4 is less efficient than ApoE3 at facilitating amyloid-beta clearance from the brain and promotes tau phosphorylation and neuroinflammation — the two pathological hallmarks of Alzheimer’s disease. Carrying one ε4 allele increases Alzheimer’s disease risk approximately three-fold compared to ε3/ε3; carrying two ε4 alleles increases risk approximately eight to twelve-fold. The ε2 allele appears to be modestly neuroprotective — ε2/ε3 carriers have a lower Alzheimer’s disease risk than ε3/ε3. It is essential that practitioners inform patients of the neurological risk dimension of APOE genotyping before the test is ordered and provide appropriate post-result counselling.

Does APOE genotype change over time or with treatment?

No. APOE genotype is determined at conception by the alleles inherited from each biological parent and remains constant in every nucleated cell throughout the patient’s entire life. It is not affected by diet, exercise, medication, illness, age, or any other physiological or environmental variable. A single APOE genotype result is definitive and permanent — repeat testing is never required for confirmation.

How does APOE ε4 affect the response to statin therapy?

ε4 carriers tend to have higher baseline LDL cholesterol than ε3/ε3 individuals under identical dietary conditions, and they typically achieve greater absolute LDL cholesterol reductions with statin therapy — in part because they start from a higher level. However, ε4 carriers have also been shown in some studies to have a less favourable LDL-C response per unit of statin dose compared to ε3 homozygotes, potentially requiring higher statin doses to achieve equivalent LDL-C reduction targets. In contrast, ε2 carriers have naturally low LDL-C and may derive limited additional benefit from statin therapy for LDL reduction, but may benefit from fibrate therapy targeting their elevated VLDL remnant burden. Understanding a patient’s APOE genotype therefore informs both the initial choice of lipid-lowering therapy and the expected response to treatment.

How does this test relate to the ApoE protein measurement in the Apolipoprotein Evaluation (BML-CAR-013)?

The APOE Genotype test (BML-CAR-015) identifies the specific ε2, ε3, and ε4 allele combination at the DNA level — providing definitive genetic characterisation that is permanent and suitable for neurological risk stratification. The Apolipoprotein Evaluation (BML-CAR-013) measures ApoE protein concentration in serum — providing the functional cardiovascular and metabolic phenotype driven by ApoE expression in the context of the patient’s current lipoprotein biology, alongside ApoB, ApoA-1, and the ApoB/ApoA-1 ratio. The two tests are complementary: APOE genotype is the definitive permanent genetic answer; ApoE protein reflects current metabolic expression. Practitioners who need genetic confirmation and neurological risk data should order BML-CAR-015. Practitioners who need the ApoE functional cardiovascular context within a broader apolipoprotein panel should order BML-CAR-013. Both can be ordered together when both dimensions are clinically required.

Which laboratory processes the APOE Genotype test on BiomarkersLabs.com?

For USA practitioners, APOE Genotype specimens are processed by Quest Diagnostics or LabCorp — CLIA-certified national reference laboratories with validated genetic testing platforms. Your patient attends their nearest Quest or LabCorp patient service centre using the requisition generated through your BiomarkersLabs.com portal. No fasting is required. For EU, UK, and Canadian practitioners, specimens are processed by IVDR-compliant regional partner laboratories with validated genetic testing capability. All processing details are confirmed in your portal at the point of ordering.

Is the APOE Genotype test available for patients in New York state?

Yes. The APOE Genotype test does not carry a New York state restriction. Licensed practitioners in New York can order this test for their patients without limitation through BiomarkersLabs.com.

How quickly will APOE Genotype results be available in my practitioner portal?

Results are available in your BiomarkersLabs.com practitioner portal within 5–7 business days from confirmed specimen receipt at the processing laboratory. Genetic testing requires additional analytical processing steps compared to standard biochemical assays, which accounts for the longer turnaround. You receive an automated email notification when results are ready. Results are accessible only through your secure verified portal — they are never sent to the patient and not accessible to anyone outside your practitioner account.